

Pancreatic Cancer and Biliary Tract Cancers: So close, So far

05 Dicembre 2025

Sala TISON - IRST IRCCS "Dino Amadori", Meldola (FC)

Evento RES accreditato ECM per 70 discenti

Medici Chirurghi (Oncologia Medica; Radioterapia; Chirurgia; Gastroenterologia; Anatomia Patologica; Radiologia);
Infermieri;
Biologi.

Responsabili Scientifici:

Giorgio Ecolani, Alessandro Passardi, Ilario Giovanni Rapposelli

Programma

10.30 Registrazione dei partecipanti

10.50 Introduzione e saluti

I SESSIONE

PDAC

Mod: Giorgio Ecolani (Chirurgia Forlì), Ilario Giovanni Rapposelli (Oncologia IRST)

- 11.10 Systemic treatment for resectable and borderline resectable disease
(Michele Reni, S. Raffaele Milano)

- 11.30 Surgeon's point of view: still room for upfront resection?
(Alessandro Zerbi, Humanitas Rozzano)

Mod: Davide Tassinari (Oncologia Rimini), Alessandro Passardi (Oncologia IRST)

- 11.50 Continuum of care in metastatic disease
(Ingrid Garajova, Parma)

- 12.10 Advanced disease: exploring new targets and role of molecular profiling
(Michele Milella, Verona)

- 12.30 Discussione

13.00 Lunch

II SESSIONE

BTC

Mod: Alessandro Cucchetti (Chirurgia Forlì), Federica Matteucci (Medicina Nucleare IRST/AUSL Romagna)

- 14.00 Ready for neoadjuvant?

(Monica Niger, INT Milano)

- 14.20 Liver transplantation at the time of immunotherapy: new opportunities, new issues

(Vincenzo Mazzaferro, INT Milano)

- 14.40 TARE and other locoregional treatments: what and when?

(Emanuela Giampalma, Radiologia Forlì)

Mod: Stefano Tamberi (Oncologia Ravenna), Paola Ulivi (Laboratorio Bioscienza IRST)

- 15.00 New treatment algorithm for advanced disease

(Andrea Casadei-Gardini, S. Raffaele Milano)

- 15.20 Comprehensive molecular dissection of BTCs and new targets to come

(Massimiliano Salati, Modena)

- 15.40 Discussione

- 16.00 Conclusione dei lavori

ABBREVIAZIONI:

PDAC - Adenocarcinoma duttale pancreatico

BTC - Tumore delle Vie Biliare

TARE – Radioembolizzazione Trans - Arteriosa

Razionale

Pancreatic cancer and biliary tract cancers have both an increasing incidence and are often diagnosed at an advanced stage, not amenable to curative treatment. Moreover, they share some clinical features such a first clinical presentation commonly associated with non-specific symptoms, and the possible appearance of jaundice, with related need for drainage. Finally, their management is strictly dependent on a multidisciplinary evaluation.

On the other hand, they have different therapeutic paths.

In pancreatic cancer, neoadjuvant therapy for resectable disease is currently an established approach. In the advanced setting, new treatment opportunities have arrived, but more are needed, and a significant contribution is awaited from a more comprehensive molecular evaluation.

In biliary tract cancer, neoadjuvant treatment for resectable disease is a new therapeutic horizon, and trials are ongoing to explore this route. In advanced disease, the advent of immunotherapy and several targeted therapies lead to unprecedented responses and long survival. As a consequence of brilliant results from new systemic therapies and of their integration with increasingly available locoregional therapies such as TARE, new scenarios are disclosed for patients, and even liver transplantation is a possible new option for selected cases.

Given these premises, in this event we aim to depict state-of-the-art therapeutic approach for pancreatic and biliary tract cancers, and try to unveil the possible future directions, always keeping focus on the necessary multidisciplinary management in order to achieve the best results for patients.